Orthometrix, Inc. (OMRX) 股價（美元）

In response to the need of an aging population driven to lead a more active and independent life, Orthometrix, Inc., a Delaware corporation ("Orthometrix"), has developed and/or acquired the rights to, technologies, procedures and devices (1) to assess musculoskeletal conditions, (2) to help restore mobility following orthopedic or neurological trauma (sports injury, hip/knee replacement, stroke); (3) to maintain or increase musculoskeletal performance and mobility which is inherent to a better quality of life; and (4) to help delay the adverse effect on mobility of certain medical conditions like Parkinson's or diabetic neuropathy. Orthometrix manages its worldwide marketing, sales, service and clinical education activities from Naples, Florida and White Plains, NY. R&D and manufacturing activities are managed by Orthometrix's manufacturing partners in Germany (XCT peripheral Quantitative Computed Tomography, Galileo/VibraFlex Whole Body Vibration, Leonardo Force Plate/Mechanography) and directly by Orthometrix in France (Oscar, Jr. DXA Phantom), and Israel (SmartStep Functional BioFeedback Therapy).